Literature DB >> 25052578

Intermittent hemodialysis treatment in cefepime-induced neurotoxicity: case report, pharmacokinetic modeling, and review of the literature.

Laila-Yasmin Mani1, Sébastien Kissling, Dragana Viceic, Bruno Vogt, Michel Burnier, Thierry Buclin, Delphine Renard.   

Abstract

Cefepime is a broad-spectrum cephalosporin indicated for in-hospital treatment of severe infections. Acute neurotoxicity, an increasingly recognized adverse effect of this drug in an overdose, predominantly affects patients with reduced renal function. Although dialytic approaches have been advocated to treat this condition, their role in this indication remains unclear. We report the case of an 88-year-old female patient with impaired renal function who developed life-threatening neurologic symptoms during cefepime therapy. She was treated with two intermittent 3-hour high-flux, high-efficiency hemodialysis sessions. Serial pre-, post-, and peridialytic (pre- and postfilter) serum cefepime concentrations were measured. Pharmacokinetic modeling showed that this dialytic strategy allowed for serum cefepime concentrations to return to the estimated nontoxic range 15 hours earlier than would have been the case without an intervention. The patient made a full clinical recovery over the next 48 hours. We conclude that at least 1 session of intermittent hemodialysis may shorten the time to return to the nontoxic range in severe clinically patent intoxication. It should be considered early in its clinical course pending chemical confirmation, even in frail elderly patients. Careful dosage adjustment and a high index of suspicion are essential in this population.
© 2014 International Society for Hemodialysis.

Entities:  

Keywords:  Hemodialysis; cefepime; drug-induced adverse event; neurotoxicity

Mesh:

Substances:

Year:  2014        PMID: 25052578     DOI: 10.1111/hdi.12198

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  7 in total

1.  Clinical characteristics and outcomes of antibiotic-associated encephalopathy in patients with end-stage kidney disease.

Authors:  Qingxiu Huang; Jianbo Li; Naya Huang; Xi Xia; Yagui Qiu; Zhong Zhong; Zhenchuan Lin; Xiaowen Huang; Dihua Zhang; Fengxian Huang
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

2.  Clinical, Electroencephalographic Features and Prognostic Factors of Cefepime-Induced Neurotoxicity: A Retrospective Study.

Authors:  Han-Tao Li; Chih-Hong Lee; Tony Wu; Mei-Yun Cheng; Wei-En Johnny Tseng; Chun-Wei Chang; Hsiang-Yao Hsieh; Hsing-I Chiang; Chih-Yin Lin; Bao-Luen Chang; Wey-Ran Lin; Siew-Na Lim
Journal:  Neurocrit Care       Date:  2019-10       Impact factor: 3.210

Review 3.  The Role of Renal Replacement Therapy in the Management of Pharmacologic Poisonings.

Authors:  Aibek E Mirrakhimov; Aram Barbaryan; Adam Gray; Taha Ayach
Journal:  Int J Nephrol       Date:  2016-11-30

4.  Cefepime-Induced Encephalopathy With Seizures in a Pediatric Patient With End-Stage Renal Disease Rapidly Reversed by High-Efficiency Hemodialysis.

Authors:  Siddharth Shah; Stephanie Bland
Journal:  Cureus       Date:  2021-03-12

5.  Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study.

Authors:  Eric Descombes; Filipe Martins; Ould Maouloud Hemett; Veronique Erard; Christian Chuard
Journal:  BMC Pharmacol Toxicol       Date:  2016-02-04       Impact factor: 2.483

Review 6.  Characterizing Cefepime Neurotoxicity: A Systematic Review.

Authors:  Ayesha A Appa; Rupali Jain; Robert M Rakita; Shahin Hakimian; Paul S Pottinger
Journal:  Open Forum Infect Dis       Date:  2017-10-10       Impact factor: 3.835

7.  Neurobehavioral Effects of Cephalosporins: Assessment of Locomotors Activity, Motor and Sensory Development in Zebrafish.

Authors:  Ying Han; Yangmin Zheng; Jingpu Zhang; Changqin Hu
Journal:  Front Pharmacol       Date:  2018-03-02       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.